Passage BIO, Inc.

Passage Bio is a clinical-stage genetic medicines company focused on developing therapies for neurodegenerative diseases of the central nervous system. The company specializes in one-time adeno-associated virus (AAV) gene therapies designed to address underlying disease pathologies. Its lead product candidate is PBFT02, a gene replacement therapy delivered via intra cisterna magna administration to elevate progranulin levels. PBFT02 is in clinical trials for frontotemporal dementia caused by progranulin deficiency and frontotemporal dementia associated with C9orf72 mutations, with potential application in amyotrophic lateral sclerosis and Alzheimer’s disease. Additionally, the company conducts a preclinical program targeting Huntington’s disease.

The company operates internationally, conducting its upliFT-D clinical trial across multi-center global sites. Preclinical and clinical development activities are supported through collaborations in the United States, including partnerships with Gemma Biotherapeutics and outsourced manufacturing relationships with Catalent in Maryland. Passage Bio's operations and pipeline development focus on patient populations in the United States and Europe.

Summary of the business section of Passage BIO's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we had 24 full-time employees.”